vs
PCB BANCORP（PCB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是PCB BANCORP的1.0倍（$30.3M vs $29.2M），REGENXBIO Inc.同比增速更快（43.0% vs 11.3%），PCB BANCORP自由现金流更多（$24.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 10.4%）
PCB BANCORP旗下的PCB银行是一家总部位于加利福尼亚州的美国社区银行，主要服务韩裔美国社群，提供商业银行服务，目前在全美8个州设有分支机构，规模在韩资背景美国银行中位列第三，仅次于希望银行与韩美银行。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PCB vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$29.2M
营收增速更快
RGNX
高出31.7%
11.3%
自由现金流更多
PCB
多$77.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
10.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $29.2M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 45.0% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 11.3% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.65 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCBRGNX
| Q4 25 | $29.2M | $30.3M | ||
| Q3 25 | $30.4M | $29.7M | ||
| Q2 25 | $29.3M | $21.4M | ||
| Q1 25 | $26.9M | $89.0M | ||
| Q4 24 | $26.2M | $21.2M | ||
| Q3 24 | $25.3M | $24.2M | ||
| Q2 24 | $24.2M | $22.3M | ||
| Q1 24 | $23.9M | $15.6M |
净利润PCBRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $11.4M | $-61.9M | ||
| Q2 25 | $9.1M | $-70.9M | ||
| Q1 25 | $7.7M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $7.8M | $-59.6M | ||
| Q2 24 | $6.3M | $-53.0M | ||
| Q1 24 | $4.7M | $-63.3M |
毛利率PCBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率PCBRGNX
| Q4 25 | 45.0% | -190.0% | ||
| Q3 25 | 52.3% | -176.3% | ||
| Q2 25 | 43.3% | -296.3% | ||
| Q1 25 | 40.2% | 13.6% | ||
| Q4 24 | 39.3% | -242.1% | ||
| Q3 24 | 42.2% | -256.6% | ||
| Q2 24 | 36.3% | -251.3% | ||
| Q1 24 | 27.2% | -408.8% |
净利率PCBRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 37.5% | -208.3% | ||
| Q2 25 | 31.0% | -331.8% | ||
| Q1 25 | 28.8% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 30.8% | -246.3% | ||
| Q2 24 | 25.9% | -237.7% | ||
| Q1 24 | 19.6% | -405.4% |
每股收益（稀释后）PCBRGNX
| Q4 25 | $0.65 | $-1.30 | ||
| Q3 25 | $0.78 | $-1.20 | ||
| Q2 25 | $0.62 | $-1.38 | ||
| Q1 25 | $0.53 | $0.12 | ||
| Q4 24 | $0.46 | $-0.99 | ||
| Q3 24 | $0.52 | $-1.17 | ||
| Q2 24 | $0.43 | $-1.05 | ||
| Q1 24 | $0.33 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $207.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $390.0M | $102.7M |
| 总资产 | $3.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCBRGNX
| Q4 25 | $207.1M | $230.1M | ||
| Q3 25 | $369.5M | $274.2M | ||
| Q2 25 | $263.6M | $323.3M | ||
| Q1 25 | $214.3M | $267.9M | ||
| Q4 24 | $198.8M | $234.7M | ||
| Q3 24 | $193.1M | $255.5M | ||
| Q2 24 | $177.6M | $290.4M | ||
| Q1 24 | $239.8M | $338.7M |
股东权益PCBRGNX
| Q4 25 | $390.0M | $102.7M | ||
| Q3 25 | $384.5M | $161.5M | ||
| Q2 25 | $376.5M | $213.7M | ||
| Q1 25 | $370.9M | $274.2M | ||
| Q4 24 | $363.8M | $259.7M | ||
| Q3 24 | $362.3M | $301.4M | ||
| Q2 24 | $353.5M | $348.3M | ||
| Q1 24 | $350.0M | $390.7M |
总资产PCBRGNX
| Q4 25 | $3.3B | $453.0M | ||
| Q3 25 | $3.4B | $525.2M | ||
| Q2 25 | $3.3B | $581.0M | ||
| Q1 25 | $3.2B | $490.9M | ||
| Q4 24 | $3.1B | $466.0M | ||
| Q3 24 | $2.9B | $519.1M | ||
| Q2 24 | $2.9B | $569.4M | ||
| Q1 24 | $2.9B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $24.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 83.6% | -174.0% |
| 资本支出强度资本支出/营收 | 7.5% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $46.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PCBRGNX
| Q4 25 | $26.6M | $-52.3M | ||
| Q3 25 | $16.4M | $-56.0M | ||
| Q2 25 | $4.9M | $-49.3M | ||
| Q1 25 | $2.3M | $33.6M | ||
| Q4 24 | $39.0M | $-31.6M | ||
| Q3 24 | $11.9M | $-40.5M | ||
| Q2 24 | $14.6M | $-45.5M | ||
| Q1 24 | $8.2M | $-55.5M |
自由现金流PCBRGNX
| Q4 25 | $24.4M | $-52.8M | ||
| Q3 25 | $16.2M | $-56.5M | ||
| Q2 25 | $3.8M | $-49.7M | ||
| Q1 25 | $1.6M | $32.6M | ||
| Q4 24 | $34.9M | $-32.7M | ||
| Q3 24 | $11.9M | $-40.9M | ||
| Q2 24 | $12.8M | $-46.0M | ||
| Q1 24 | $6.0M | $-56.0M |
自由现金流率PCBRGNX
| Q4 25 | 83.6% | -174.0% | ||
| Q3 25 | 53.2% | -189.9% | ||
| Q2 25 | 13.1% | -232.8% | ||
| Q1 25 | 6.0% | 36.6% | ||
| Q4 24 | 133.2% | -154.2% | ||
| Q3 24 | 46.8% | -168.9% | ||
| Q2 24 | 53.1% | -206.2% | ||
| Q1 24 | 25.2% | -358.5% |
资本支出强度PCBRGNX
| Q4 25 | 7.5% | 1.7% | ||
| Q3 25 | 0.8% | 1.7% | ||
| Q2 25 | 3.7% | 1.8% | ||
| Q1 25 | 2.8% | 1.2% | ||
| Q4 24 | 15.5% | 5.1% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 7.3% | 2.1% | ||
| Q1 24 | 9.3% | 3.6% |
现金转化率PCBRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.30× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 2.33× | — | ||
| Q1 24 | 1.76× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
